NASDAQ:NRXS NeurAxis (NRXS) Stock Price, News & Analysis $6.00 -0.02 (-0.33%) As of 08/28/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About NeurAxis Stock (NASDAQ:NRXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NeurAxis alerts:Sign Up Key Stats Today's Range$5.94▼$6.1150-Day Range$5.96▼$7.3152-Week Range$2.21▼$9.33Volume40,207 shsAverage Volume132,540 shsMarket Capitalization$75.35 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company Overview NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders. NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements. Its lead programs are designed to modulate key pathways involved in neuronal survival and regeneration, with preclinical and early-stage clinical studies underway to assess safety, pharmacokinetics and proof of concept. Headquartered in the United States, NeurAxis engages with international partners to support its translational and clinical development activities. The company’s common shares trade on the Nasdaq Stock Market under the ticker symbol NRXS.AI Generated. May Contain Errors. Read More Receive NRXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRXS Stock News HeadlinesNeurAxis Enhances Executive and Director Equity CompensationAugust 19, 2026 | tipranks.comNeurAxis (NRXS) Q2 2026 Earnings Call TranscriptAugust 12, 2026 | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.August 29 at 1:00 AM | Porter & Company (Ad)Neuraxis Inc (NRXS) (Q2 2026) Earnings Call Highlights: Revenue Surges 116% as Payer Coverage ...August 11, 2026 | finance.yahoo.comNeurAxis, Inc. (NRXS) Q2 2026 Earnings Call TranscriptAugust 11, 2026 | seekingalpha.comNeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue GrowthAugust 11, 2026 | markets.businessinsider.comNeurAxis Announces Additional Mid-Atlantic Coverage for IB-Stim PENFS Therapy, Expanding Access to Over 500,000 LivesAugust 4, 2026 | quiverquant.comQNeurAxis Expands Payer Coverage with New PoliciesAugust 4, 2026 | globenewswire.comSee More Headlines NRXS Stock Analysis - Frequently Asked Questions How have NRXS shares performed this year? NeurAxis' stock was trading at $4.54 at the start of the year. Since then, NRXS stock has increased by 32.2% and is now trading at $6.00. How were NeurAxis' earnings last quarter? NeurAxis, Inc. (NASDAQ:NRXS) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.25) earnings per share (EPS) for the quarter. The firm had revenue of $0.67 million for the quarter. When did NeurAxis IPO? NeurAxis (NRXS) raised $7 million in an initial public offering (IPO) on Wednesday, August 9th 2023. The company issued 1,098,667 shares at $6.00 per share. Who are NeurAxis' major shareholders? Top institutional shareholders of NeurAxis include AIGH Capital Management LLC (4.17%), Panoramic Capital LLC (0.92%), BlackRock Inc. (0.47%) and Elevation Point Wealth Partners LLC (0.11%). Insiders that own company stock include Brian Allen Carrico, Thomas Joeseph Carrico, Timothy Robert Henrichs and Corp Masimo. View institutional ownership trends. How do I buy shares of NeurAxis? Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeurAxis own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeurAxis investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Outdoor (POWW), SPDR S&P 500 ETF Trust (SPY), TJX Companies (TJX) and ETRACS Crude Oil Shares Covered Call ETN (USOI). Company Calendar Last Earnings11/12/2024Today8/29/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:NRXS CIK1933567 Webneuraxis.com Phone(812) 689-0791FaxN/AEmployees19Year Founded2011Price Target and Rating Average Price Target for NeurAxis$13.00 High Price Target$13.00 Low Price Target$13.00 Potential Upside/Downside+116.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.63 million Net Margins-492.76% Pretax Margin-341.35% Return on EquityN/A Return on Assets-641.25% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.23 Sales & Book Value Annual Sales$5.32 million Price / Sales14.17 Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-22.22Miscellaneous Outstanding Shares12,558,000Free Float6,085,000Market Cap$75.35 million OptionableNot Optionable Beta1.49 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:NRXS) was last updated on 8/29/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeurAxis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
